Long-term Macrolide Therapy; Oropharyngeal Dysbiosis And The Spread Of Resistant Pathogens
Funder
National Health and Medical Research Council
Funding Amount
$384,153.00
Summary
Use of macrolide therapy for chronic lung diseases is increasing rapidly. We will determine the impact of long-term macrolide antibiotic use on upper airway bacteria in patients with lung disease, and assess its contribution to antibiotic resistance in the wider community. We will investigate the mechanism by which this therapy achieves benefit and assess interference with bacterial signalling as a means to improve treatment efficacy and reduce induction of antibiotic resistance.
A Multi-centre Double-blind RCT On Community-acquired Pneumonia In Indigenous Children And A Developing Country: Improving Clinical Outcomes And Identifying Systemic Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$2,167,560.00
Summary
Young children of Indigenous communities and developing countries are often hospitalised for pneumonia and have high risk of subsequent chronic disease. Our international study will determine if a longer duration of antibiotics (compared to shorter duration) improves the short and long term clinical outcomes of children hospitalised for pneumonia. We will look for unique markers that may predict those who will develop chronic lung disease. Our study will influence future guidelines on pneumonia.
Bronchiectasis And Infection With The Human T-lymphotropic Virus 1 Among Indigenous Australians
Funder
National Health and Medical Research Council
Funding Amount
$849,674.00
Summary
The Indigenous people of Central Australia have the highest reported prevalence of bronchiectasis in the world. In a recent study, we found infection with Human T -cell Lymphotropic Virus type 1 (HTLV-1) may contribute to the devlopment of bronchiectasis. The present study seeks to confirm this association and to determine whether increased HTLV-1 activity is associated with greater risk. This will require the development of assays that will improve diagnosis and assist in determining prognosis ....The Indigenous people of Central Australia have the highest reported prevalence of bronchiectasis in the world. In a recent study, we found infection with Human T -cell Lymphotropic Virus type 1 (HTLV-1) may contribute to the devlopment of bronchiectasis. The present study seeks to confirm this association and to determine whether increased HTLV-1 activity is associated with greater risk. This will require the development of assays that will improve diagnosis and assist in determining prognosis of HTLV infection.Read moreRead less
Multicentre Randomised Controlled Trial To Improve The Management Of Exacerbations In Children With Bronchiectasis
Funder
National Health and Medical Research Council
Funding Amount
$1,185,057.00
Summary
Our national study aims to improve the management of acute exacerbations of bronchiectasis in children, a condition that is common in Indigenous people worldwide. Results will impact on national and international guidelines and substantially advance knowledge on exacerbations of childhood bronchiectasis.